Does GMED pay a dividend and is it safe?

Globus Medical Inc. (GMED) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / GMED / dividends

PODD (72) BAX (50) PEN (57) SOLV (44) ⌘ Pro Terminal →

Globus Medical Inc. (GMED) Dividend Safety Gauge & 10-Year DRIP Compounder

$79.46 +1.81% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $79.57

Globus Medical Inc. (GMED) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $10.48B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GMED Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GMED stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Globus Medical Inc. (NYSE: GMED) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $79.46 (+1.81% 1D, market cap $10.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, GMED ranks #83 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GMED compare to PODD and BAX in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), GMED carries a Roarable C+ (69/100 RQD), trailing P/E of 20.7x, gross margin of 67.4%, and ROIC of 8.7%. By comparison, PODD (Insulet Corporation) holds a B grade (72/100 RQD, P/E 42.8x, ROIC 20.4%, cap $10.38B) and BAX (Baxter International Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -2.4%, cap $11.90B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GMED?

▼

Per GMED's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001237831), Globus Medical Inc. generated $2.94B in revenue (+16.7% YoY), $537.9M in net income, and $588.8M in free cash flow against $5.30B in total assets and $328.3M in total debt. Key quantitative strengths: Strong cash generator (67% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $79.57 (+0.14%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 20% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GMED)Realized 20D OHLCV Swing Band: ±6%

Deterministic 5-Pillar Attribution (69/100 Composite)

🔍 WHY GMED SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (26% of score)

Altman Z-Score 10.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 20% FCF Margin ($588.8M FCF) & 67.4% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$76.31+3.1% Next Q

Q2 (-2Q)

Grade C+$78.68+3.3% Next Q

Q3 (-1Q)

Grade B-$81.26-2.2% Next Q

Current

Grade C+$79.46+2% Hist 90D α

Trajectory: C (61) → C+ (69)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the GMED Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, GMED faces multiple-compression risk if 20.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 64.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($77.41) or 200D SMA ($83.31) invalidates the momentum regime and cuts Target Base ($83.39) toward Bear Floor ($65.04).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GMED• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GMED Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 69%NO 31%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (11% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $28,394

Est. Year-10 Shareholder Yield: $511/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.1K

Yr 1

$12.3K

Yr 2

$13.7K

Yr 3

$15.2K

Yr 4

$16.9K

Yr 5

$18.7K

Yr 6

$20.8K

Yr 7

$23.0K

Yr 8

$25.6K

Yr 9

$28.4K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in GMED & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on GMED and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GMED // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.30%📐 HORIZONTAL RANGE

2026-11-03O $82.91H $82.91L $78.05C $79.46VOL 1.68M

RES: $82.99SUP: $72.17SMA50: $77.41SMA200: $83.31

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GMED Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GMED Butterfly Map → + Track GMED →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

14.3%/yr Implied 5Y Growth

vs. +16.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GMED today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GMED. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GMED today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GMED)

Health Care Rank #83 of 1016 ⚔️ PODD vs GMED Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GMED vs. PODD, BAX, PEN, SOLV)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Globus Medical Inc. (GMED) ranks #83 by composite RQD confidence (69/100, grade C+) and #104 by equity capitalization ($10.48B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with GMED at 69/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GMED ACTIVE Globus Medical Inc.	C+	69/100	20.7x	67.4%	8.7%	+1.81%	$10.48B	Benchmark Subject
PODD Insulet Corporation	B	72/100	42.8x	71.6%	20.4%	+2.63%	$10.38B	/podd-vs-gmed →
BAX Baxter International Inc.	D	50/100	—	30.1%	-2.4%	+5.30%	$11.90B	/bax-vs-gmed →
PEN Penumbra Inc.	D+	57/100	71.4x	67.1%	10.6%	+0.75%	$12.57B	/pen-vs-gmed →
SOLV Solventum Corporation	D	44/100	9.1x	53.5%	18.7%	+4.21%	$13.84B	/solv-vs-gmed →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001237831

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Globus Medical Inc. (GMED) reported GAAP revenue of $2.94B (+16.7% vs. FY2024 revenue of $2.52B , and +87.4% cumulative change since FY2023) , GAAP net income of $537.9M, operating cash flow of $753.4M, and free cash flow of $588.8M (+45.3% YoY). On the balance sheet, GMED closed FY2025 with $5.30B in total assets against $328.3M in total debt (Altman Z-Score: 10.74, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.94B	$537.9M	$753.4M	$588.8M	$5.30B	$328.3M
FY2024 (FY)	2024-12-31	$2.52B	$103.0M	$520.6M	$405.2M	$5.25B	$483.5M
FY2023 (FY)	2023-12-31	$1.57B	$122.9M	$243.5M	$172.9M	$6.12B	$1.43B

3. GMED Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GMED stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GMED compare to PODD and BAX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GMED?

Where is GMED trading relative to its 50-day, 200-day, and 52-week technical levels?

GMED last traded at $79.46 (+1.81% on volume of 1,513,192 shares), positioning the stock +2.65% above its 50-day simple moving average ($77.41) and -4.62% below its 200-day simple moving average ($83.31). Across its 52-week range of $59.51 to $101.40, GMED sits at the 47.6% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.0% ($74.69 to $84.23).

Direct Sub-Reports: GMED RQD Cockpit GMED 12M Forecast GMED Earnings & Move GMED Dividends & DRIP GMED Insiders & 13F GMED Whale Options GMED Profit Sankey GMED News & Why

ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GMED — Globus Medical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:16:03Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

GMED scores 72 out of 100 with a letter grade of B and the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are: Fundamental Cash Engine at 16/20 (ROIC 8.7%; FCF yield 5.29%), Whale 13F Flow at 12/20 (institutional accumulation and options positioning), Insider Conviction at 15/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.07; sector sensitivity), and Forensic Balance Sheet at 18/20 (Altman Z 10.74; Piotroski F 9/9; Debt/Equity 0.07). The strongest pillar is the forensic balance sheet, which indicates low financial-distress risk per the metrics provided. The weakest is macro regime fit, where the beta of 1.07 implies the stock has moved slightly more than the market in the source's framing, so broader market weakness could carry through to the shares. Upside drivers in the source data are the cash-generation metrics and the balance-sheet strength. Valuation tradeoffs are visible in the multiples: a trailing P/E of 20.7 compared with a forward P/E of 17.4 and EV/EBITDA of 17.6. Whale-flow and macro pillars are the lower-scoring components and merit closer monitoring. This is an analytical summary of the source data, not personalized advice.

2. Business Model, Unit Margins & SEC Financial Trajectory

Globus Medical Inc. (GMED) is a NYSE-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Beyond the sector and industry classification, the product lines, customer base, and revenue model are — The source does record a gross margin of 67.4%, an operating margin of 16.3%, and a net margin of 18.3%.

Revenue rose across the three reported periods, from $1.57B to $2.94B, and net income in FY 2025 ($537.9M) exceeded operating income ($479.8M). Per the market data, the net margin is 18.3% and ROIC is 8.7%. The source provides a forensic balance-sheet score of 18/20, with an Altman Z-Score of 10.74, a Piotroski F-Score of 9/9, and a Debt/Equity ratio of 0.07. Reported debt fell from $1.43B in FY 2023 to $328.3M in FY 2025.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Forensic balance sheet scores 18/20 with an Altman Z-Score of 10.74, a Piotroski F-Score of 9/9, and Debt/Equity of 0.07, with debt reduced from $1.43B in FY 2023 to $328.3M in FY 2025. With Fundamental Cash Engine at 16/20 (ROIC 8.7%, FCF yield 5.29%) and Institutional Whale Flow at 9/20, sustained execution supports upside toward the top of the $59.51 – $101.40 52-week range.
🐻 Primary Bear Case: Macro regime fit scores only 11/20 with a beta of 1.07, and analysts are reported as split, with a fair value cut flagged as a RED risk-watch item. Investors must weigh 20.7x trailing P/E and 17.6x EV/EBITDA against 16.3% operating margins and a 1.07 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), GMED carries a macro regime beta of 1.07 and gross margin of 67.4%.

Key Question #1: What is the basis for the "modest fair value cut" and the analyst split referenced in the risk-watch headline?
Key Question #2: What are the reported EPS figures, since the financials show EPS as N/A for all periods?
Key Question #3: What caused the sharp swing in net income between FY 2024 ($103.0M) and FY 2025 ($537.9M)?

GMED Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Globus Medical Inc. (GMED) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GMED Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 20h ago

Globus Medical (GMED) Stock Sees Modest Fair Value Cut As Analysts Split On Outlook

Yahoo Finance report covering Globus Medical Inc. (GMED) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ChartMill • 23h ago

Globus Medical (NYSE:GMED): A Quality Investing Case Built on Durable Growth

ChartMill report covering Globus Medical Inc. (GMED) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Globus Medical (GMED) Stock Looks Undervalued Even After A 77% Run

Yahoo Finance report covering Globus Medical Inc. (GMED) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Globus Medical (NYSE:GMED) Stock Forecast & Analyst Predictions

Simply Wall St report covering Globus Medical Inc. (GMED) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Globus Medical Q2 2026 Earnings Call Transcript - Globus Medical (NYSE:GMED)

Benzinga report covering Globus Medical Inc. (GMED) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ChartMill • 1d ago

Globus Medical (NYSE:GMED): A Balanced Affordable Growth Case

ChartMill report covering Globus Medical Inc. (GMED) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Reasons to Add Globus Medical Stock to Your Portfolio Now

Yahoo Finance report covering Globus Medical Inc. (GMED) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 1d ago

A new platform is designed to let surgeons tailor spinal implants to each patient. Globus Medical will preview it at NASS.

Stock Titan report covering Globus Medical Inc. (GMED) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GMED Bull vs. Bear Conversation Board — What's Your Call at $79.46?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GMED 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 Options Flow Specialist 🐂 BULLISH 🎯 Target: $96.78 (+24.0%)

📌 Pinned Debate

Forensic balance sheet scores 18/20 with an Altman Z-Score of 10.74, a Piotroski F-Score of 9/9, and Debt/Equity of 0.07, with debt red

Here is why I am bullish on GMED here at $78.05: Forensic balance sheet scores 18/20 with an Altman Z-Score of 10.74, a Piotroski F-Score of 9/9, and Debt/Equity of 0.07, with debt reduced from $1.43B in FY 2023 to $328.3M in FY 2025.. Compare GMED's 16.3% operating margin and 8.7% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $74.15 are getting bought.

VolSurface_Trader 🐂 BULL

@BearTrap_Alert Shorting a 9/20 institutional whale-flow stock at $78.05 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $61.66 (-21.0%)

Spot @ $78.05

Macro regime fit scores only 11/20 with a beta of 1.07, and analysts are reported as split, with a fair value cut flagged as a RED risk

Sitting on the sidelines or leaning short GMED above $78.05. Macro regime fit scores only 11/20 with a beta of 1.07, and analysts are reported as split, with a fair value cut flagged as a RED risk-watch item.. Until Fundamental Cash Engine (16/20) and FCF yield (5.29%) inflect higher, upside is capped near $101.40.